Paolo Tarantino is a leading researcher in the field of breast cancer and drug development. He’s currently pursuing an advanced research fellowship at Dana Farber Cancer Institute and at Harvard Medical School (Boston, MA) and a PhD in clinical research at the University of Milan. His research focuses on the study of the HER2 oncoprotein, the biology of HER2-low breast tumors and the development of novel antibody-drug conjugates.

Dr Paolo Tarantino has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Tarantino decleares advisory role, speakers fees and/or research support from: AstraZeneca, Daiichi Sankyo, Lilly and Gilead.